Evidence map›Paper›PMID 35424294›Full record

ArticleRSC advances2021

Synthesis of 2-ethoxycarbonylthieno[2,3-

Xu-Yang Mu, Zhi-Jia Wang, Bo Feng, Lei Xu, Li-Xin Gao, Rajendran Satheeshkumar, Jia Li, Yu-Bo Zhou, Wen-Long Wang

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xu-Yang MuSchool of Pharmaceutical Sciences, Jiangnan University Wuxi 214122 China wwenlong2011@163.com.
Zhi-Jia WangSchool of Pharmaceutical Sciences, Jiangnan University Wuxi 214122 China wwenlong2011@163.com.
Bo FengSchool of Pharmaceutical Sciences, Jiangnan University Wuxi 214122 China wwenlong2011@163.com.
Lei XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China ybzhou@simm.ac.cn.
Li-Xin GaoState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China ybzhou@simm.ac.cn.
Rajendran SatheeshkumarSchool of Pharmaceutical Sciences, Jiangnan University Wuxi 214122 China wwenlong2011@163.com.ORCID https://orcid.org/0000-0001-8492-286X
Jia LiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China ybzhou@simm.ac.cn.
Yu-Bo ZhouState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China ybzhou@simm.ac.cn.
Wen-Long WangSchool of Pharmaceutical Sciences, Jiangnan University Wuxi 214122 China wwenlong2011@163.com.ORCID https://orcid.org/0000-0002-0324-3003
Jiangnan University · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of 2-ethoxycarbonylthieno[2,3-

Identifiers

PMID35424294
PMCPMC8694002
OpenAlexW3120077677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.